# An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)

> **NCT01742793** · PHASE1 · TERMINATED · sponsor: **Yale University** · enrollment: 12 (actual)

## Conditions studied

- Hodgkin's Lymphoma
- Mature T-cell Lymphoma
- Multiple Myeloma

## Interventions

- **DRUG:** lenalidomide (Revlimid) and romidepsin (Istodax)

## Key facts

- **NCT ID:** NCT01742793
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10
- **Primary completion:** 2016-08
- **Final completion:** 2016-08
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** The study was terminated due to withdrawal of institutional support, Phase II never began.
- **Last updated:** 2020-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01742793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01742793, "An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01742793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*